The Federal Circuit has upheld its decision to prevent MSN Pharmaceuticals from launching a generic version of Novartis’ popular cardiovascular medication, Entresto. The decision comes as Novartis continues to argue its position for an injunction that could extend through July.
This case highlights ongoing tensions in the pharmaceutical industry regarding the introduction of generic drugs, particularly when it involves top-selling medications. The litigation remains a pivotal example of the intricate balance between intellectual property rights and market competition.
For further details, the original report is available through Law360.